Physician profile
Anne E Gillis
NPI 1225006869
$2,310.03
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $304 · 2021: $611 · 2022: $458 · 2023: $726 · 2024: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.49 | 2021-2024 | |
| Allergan, INC. | $171.03 | 2019-2021 | |
| Glaxosmithkline, LLC. | $157.03 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $146.41 | 2019-2023 | Ozempic, Rybelsus |
| Corcept Therapeutics | $129.81 | 2023 | Korlym |
| Amgen INC. | $126.48 | 2020-2022 | |
| Esperion Therapeutics, INC. | $118.02 | 2020-2022 | |
| Pfizer INC. | $79.85 | 2019-2024 | |
| Exact Sciences Corporation | $69.17 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $68.30 | 2022-2023 | |
| Astellas Pharma US INC | $59.32 | 2020-2021 | |
| Amarin Pharma, INC. | $55.13 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $53.60 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $48.24 | 2023 | Rexulti |
| Lilly USA, LLC | $41.13 | 2021-2023 | Mounjaro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38.37 | 2019-2020 | |
| Mannkind Corporation | $27.99 | 2021 | |
| Ibsa Pharma INC. | $27.24 | 2022-2023 | Tirosint, Licart |
| Axsome Therapeutics, INC. | $25.72 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $23.85 | 2020 | |
| Supernus Pharmaceuticals, INC. | $19.88 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $19.56 | 2021 | |
| Biogen, INC. | $17.67 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.62 | 2021 | |
| Daiichi Sankyo INC. | $16.33 | 2022 | |
| Qol Medical, LLC | $16.04 | 2023 | Sucraid |
| Amryt Pharma Holdings LTD | $14.66 | 2021 | |
| Abbott Laboratories | $14.49 | 2021 | |
| Medtronic, INC. | $12.43 | 2022 | |
| Smith+Nephew, INC. | $12.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Gillis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.